Immunotherapy has revolutionized cancer treatment, yet many patients do not respond. Here, we profile the proteome and phosphoproteome of clinical pre-treatment samples from 73 esophageal squamous cell carcinoma (ESCC) patients undergoing anti-programmed death 1 (PD1) immunotherapy.